← All Century Therapeutics, INC filings

Century Therapeutics, INC 8-K filings

NASDAQ
IPSC
Century Therapeutics, INC
8-K: Century Therapeutics Expands Autoimmune Pipeline with $60 Million Raise and Clade Acquisition
Century Therapeutics is bolstering its autoimmune disease efforts with a $60 million private placement and the acquisition of Clade Therapeutics, enhancing its pipeline and technology.
NASDAQ
IPSC
Century Therapeutics, INC
8-K: Century Therapeutics Advances iPSC-Derived Cell Therapy Platform with Promising Clinical Data and Expanded Pipeline
Century Therapeutics is progressing its next-generation allogeneic iPSC-derived cell therapy platform, showcasing encouraging early clinical data and expanding its pipeline in oncology and autoimmune diseases.
NASDAQ
IPSC
Century Therapeutics, INC
8-K: Century Therapeutics Presents Promising Preclinical Data on iPSC-Derived Cell Therapy Platform at AACR 2024
Century Therapeutics showcased preclinical data at the AACR Annual Meeting 2024, highlighting advancements in their iPSC-derived cell therapy platform, including novel CAR designs and Allo-Evasion technology.
NASDAQ
IPSC
Century Therapeutics, INC
8-K: Century Therapeutics Reports Full Year 2023 Results and Provides Business Update, Highlighting Progress in Cell Therapy Development
Century Therapeutics announced its full year 2023 financial results and provided a business update, showcasing promising initial data from its Phase 1 ELiPSE-1 trial and progress in its iPSC-derived cell therapy platform.
NASDAQ
IPSC
Century Therapeutics, INC
8-K: Century Therapeutics CFO Resigns, Interim Replacement Named
Century Therapeutics' Chief Financial Officer, Michael C. Diem, M.D., has resigned effective February 2, 2024, with Douglas Carr named as interim Principal Financial Officer.